Chai Discovery Raises $400 Million for AI-Designed Medicines
The molecular design startup reached a $3.8 billion valuation while expanding partnerships with major drugmakers.
Archive
The molecular design startup reached a $3.8 billion valuation while expanding partnerships with major drugmakers.
The biotechnology company plans to move nonviral treatments for Duchenne muscular dystrophy and polycystic kidney disease toward clinical testing.
The Redwood City company will scale access to an FDA-cleared prescription belt designed for people with low bone density.